

Applicants: David J. Pinsky, et al.
Serial No.: 08/721,447 (CPA)
Filed: August 12, 1999
Page 2

FOR TREATING AN ISCHEMIC DISORDER COMPRISING ADMINISTERING AN ANTAGONIST OF FACTOR IX ACTIVITY--.

In the specification:

On page 30, line 15, please replace "Prime-A-Gene" with --Prime-A-GeneTM--.

On page 30, line 17, please replace "X-Omat" with --X-OmatTM--.

On page 48, line 3, please replace "Enzymobeads" with --EnzymobeadsTM--.

On page 48, line 7 and line 23, please replace "Sigma" with --SigmaTM--.

On page 48, line 19, please replace "Becton-Dickinson" with --Becton-DickinsonTM--.

On page 48, line 27, please replace "Gibco" with --GibcoTM--.

On page 51, line 16, please replace "Bio-Rad" with --Bio-RadTM--.

On page 68, line 15, please replace "Zeiss" with --ZeissTM--.

On page 77, line 30, please replace "BALB/C" with --BALB/c--.

In the Claims:

Please cancel claims 47-48 without prejudice to applicants' right to pursue the subject matter of these claims in a future application.

Please amend claims 46, 49 and 50 as follows:

EI --46. (amended) A method for treating an ischemic disorder in a subject which comprises administering to the subject an antagonist of Factor IX activity in a pharmaceutically acceptable form [or chemically